OR WAIT null SECS
October 19, 2022
Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.
Ebvallo (tabelecleucel) would be the first EMA-approved therapy for patients with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Takeda’s dengue vaccine is designed to prevent disease caused by virus serotypes 1, 2, 3, and 4 in individuals four and older.
October 14, 2022
Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.
Alexion’s acquisition of LogicBio is designed to accelerate the company’s growth in genomic medicines.
October 12, 2022
Eli Lilly and Company will partner with Schrödinger to develop and optimize small molecule compounds.
October 10, 2022
Amphista Therapeutics and Domainex will work together to develop treatments focusing on targeted protein degradation.
October 04, 2022
FDA has granted Fast Track designation for CUE-101, a treatment of recurrent/metastatic head and neck squamous cell carcinoma.
Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.
September 30, 2022
Novo Nordisk will pay up to $700 million for the exclusive rights to develop and commercialize candidates from Ventus Therapeutics NLRP3 inhibitor portfolio.